You are here: Urology Textbook > Drugs in Urology > Alpha blocker > Alfuzosin
Alfuzosin: Side Effects and Dosage
- Alpha blockers: General pharmacology
- Alpha blocker Alfuzosin
- Alpha blocker Doxazosin
- Alpha blocker Silodosin
- Alpha blocker Tamsulosin
- Alpha blocker Terazosin
Mechanism of Action of Alfuzosin
Alfuzosin is a nonselective α1-blocker with short elimination half-life; sustained-release formulation is available. Please see section general pharmacology of alpha blocker. Review Literatur: (Chapple, 2004).
Indications for Alfuzosin
- Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
- Off-label treatment of female LUTS due to neurogenic bladder neck obstruction.
- Off-label treatment: improve the spontaneous passage of distal ureteral stones.
Pharmacokinetics of Alfuzosin
Elimination half-life: 9 h for the sustained-release formulation.
Increased side effect profile, since alfuzosin is a nonselective α1 blocker.
- Initial hypotension, orthostatic collapse, reflex tachycardia, usually transient.
- Increased risk (HR 1,2) of cardiac failure in patients with cardiac comorbidity (Lusty et al., 2021).
- Stuffy nose
- Retrograde ejaculation
- Dizziness, weakness.
Contraindications of Alfuzosin
Conservative treatment of BPH is not indicated if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections, and bladder stones.
Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.
Alfuzosin should be paused for cataract surgery to prevent an intraoperative floppy iris syndrome.
Dosage of Alfuzosin
10 mg in retarded galenic formulation orally once daily or 5 mg 1–0–1. The initial or single dose should be given before bedtime in the evening to reduce side effects.
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Chapple 2004 CHAPPLE, C. R.:
Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
J. Nordling, “Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia,” BJU Int, vol. 95, no. 7, pp. 1006–12, 2005.
Deutsche Version: Alfuzosin